Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.

Loading...
Thumbnail Image

Embargo End Date

Authors

Gregucci, F
Spada, S
Barcellos-Hoff, MH
Bhardwaj, N
Chan Wah Hak, C
Fiorentino, A
Guha, C
Guzman, ML
Harrington, K
Herrera, FG
Honeychurch, J
Hong, T
Iturri, L
Jaffee, E
Karam, SD
Knott, SRV
Koumenis, C
Lyden, D
Marciscano, AE
Melcher, A
Mondini, M
Mondino, A
Morris, ZS
Pitroda, S
Quezada, SA
Santambrogio, L
Shiao, S
Stagg, J
Telarovic, I
Timmerman, R
Vozenin, M-C
Weichselbaum, R
Welsh, J
Wilkins, A
Xu, C
Zappasodi, R
Zou, W
Bobard, A
Demaria, S
Galluzzi, L
Deutsch, E
Formenti, SC

Document Type

Journal Article

Date

2023-12-31

Date Accepted

2023-06-02

Abstract

Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.

Citation

OncoImmunology, 2023, 12 (1), pp. 2222560 -

Source Title

OncoImmunology

Publisher

TAYLOR & FRANCIS INC

ISSN

2162-4011

eISSN

2162-402X
2162-402X

Collections

Research Team

Trans Immunotherapy
Targeted Therapy

Notes